A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LUCAR-G39P, a Dual-targeted Cell Preparation Targeting CD19/CD20, in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
LUCAR-G39P is positioned in the competitive landscape of CAR-T therapies, specifically targeting relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Given the increasing prevalence of NHL and the limitations of existing therapies, this dual-targeted approach may enhance efficacy and reduce relapse rates. The trial's termination after achieving proof of concept suggests potential for further development, possibly leading to a Phase II study. Collaboration with Nanjing Legend Biotech Co. indicates strategic partnerships that may enhance market access and resource allocation. The asset's success could capture a significant share of the CAR-T market, which is projected to grow substantially in the coming years.
Indication: Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Modality: protein therapy
Target: CD19/CD20 dual-targeted cell preparation
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD19/CD20 dual-targeted cell preparation
View original source fields
Condition raw: Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Condition normalized: Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: CD19/CD20 dual-targeted cell preparation
Target normalized: CD19/CD20 dual-targeted cell preparation